The mircoRNA expression profiles of human temporal lobe epilepsy in HS ILAE type 1
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA512243 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR8380722.fastq.gz | Fastqsanger.gz | |||
| SRR8380723.fastq.gz | Fastqsanger.gz | |||
| SRR8380724.fastq.gz | Fastqsanger.gz | |||
| SRR8380725.fastq.gz | Fastqsanger.gz | |||
| SRR8380726.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 6 |
Similar Datasets
Project description:Temporal lobe epilepsy (TLE) is associated with neurodegeneration, often leading to hippocampal sclerosis (HS). The type 1 HS, which is characterized by severe neuronal cell loss and gliosis predominantly in regions CA1 and CA4, is the most common subtype and is associated with best prognosis according to ILAE classification system. MiRNAs are participate in the biological processes underlying many nervous system diseases including epilepsy. However, the miRNA expression profile of HS ILAE type 1 is not completely understood. A total of 14 patients were identified as having the ILAE subtype, as determined by NeuN immunohistochemistry (ILAE type 1=7; no-HS=7). Next-generation sequencing and reverse transcription polymerase chain reaction technology was used to validate the dysregulated miRNAs. Bioinformatics analysis of the predicted target gene was conducted using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis. In total, 1643 mature miRNAs were detected in this study, along with 5 miRNAs were upregulated and 2 miRNAs were downregulated expression in the type 1 group. Bioinformatics analysis showed that 1545 target genes were predicted using miRDB and Targetscan databases, and these predicted genes showed enrichment in the pathway associated with nucleic acid binding, intracellular and cellular macromolecule metabolic processes, and the PI3K-Akt signaling pathway. This study is the first to report the miRNA expression profile of HS ILAE type 1 compared with no-HS. These results provide new insights into the neuron loss pathology and offer fundamental evidence as to why there is a good prognosis among patients with type 1 HS.
2019-01-01 | GSE124507 | GEO
Project description:Differential DNA methylation profiles of HS ILAE type 1 in human temporal lobe epilepsy
| PRJNA590471 | ENA
Project description:Ion channel splice array data collected from temporal neocortex brain tissue collected from patients with mesial temporal lobe epilepsy. Temporal cortex samples from control subjects were compared to temporal neocortex of patients with mesial temporal lobe epilepsy
2010-06-11 | E-GEOD-6773 | biostudies-arrayexpress
Project description:The epilepsies represent one of the most common neurological disorders. Mesial temporal lobe epilepsies (MTLE) are the most frequent form of partial epilepsies and display frequent resistance to anti-epileptic drugs thus representing a major health care problem. In TLE, the origin of seizure activity typically involves the hippocampal formation, which displays major neuropathological features, described with the term hippocampal sclerosis (HS). HS is the most frequent pathological substrate of refractory mesial temporal lobe epilepsy. Complex partial seizures (CPS) are the predominant seizure type associated with medial temporal lobe epilepsy. MTLE is commonly due to mesial temporal sclerosis (MTS). The biology underlying the epilepstic seizures and the transcriptome associated to the seizure in intractable medial temporal lobe epilepsy is ill understood. The aim of the study was to identify potential biomarkers that could identify epileptic seizure. Thus we performed transcriptome profiling of ten medial temporal lobe epilepsy cases which are resistant to the drug and underwent temporal lobectomy. The cases constitutes of patients with intractable complex partial seizure, treated medically and have undergone detailed presurgical evaluation and subjected to surgery for standard temporal lobectomy and amygdalo-hippocampectomy. The spiking areas identified after the electrocorticography will form the test tissues, which compared with the nonspiking areas removed during the surgery, from the same patient. This could probably form one of the appropriate controls, as test and control are from same patient, which eliminates the genome variations that could incur due to the comparison with the tissues from the another patient. Also this could get rid of expression changes due to the treatments undergone by the patient. We performed two color microarray wherein we labled seizure focus (spiking area) with Cy5 and non-seizure region tissues (non-spiking) with Cy3. As a strategy to test the possibility of potential diagnostic biomarkers we are intended to test the differentially regulated molecules in an independent set of epilepsy samples. Two color experiment
2012-12-01 | E-GEOD-25453 | biostudies-arrayexpress
Project description:Ion channel splice array data from temporal cortex brain tissue samples collected from control subjects (no mesial temporal lobe epilepsy). Keywords: disease associated splicing changes Temporal cortex samples from control subjects were compared to temporal neocortex of patients with mesial temporal lobe epilepsy
2007-01-23 | E-GEOD-6771 | biostudies-arrayexpress
Project description:This SuperSeries is composed of the following subset Series: GSE6771: Temporal Cortex Control (mesial temporal lobe epilepsy control) GSE6773: Temporal neocortex mesial temporal lobe epilepsy GSE6774: Temporal Cortex Control (Alzheimer's disease control) GSE6775: Temporal Cortex Alzheimer's Disease GSE6777: Cerebellum Alzheimer's Disease GSE6778: Cerebellum Control (Alzheimer's disease control) Keywords: SuperSeries Refer to individual Series
2007-01-23 | E-GEOD-6834 | biostudies-arrayexpress
Project description:Temporal Lobe Epilepsy and Retrotransposons
| PRJNA647483 | ENA
Project description:Temporal Lobe Epilepsy and Retrotransposons
| PRJNA647484 | ENA
Project description:Mesial temporal lobe epilepsy (mTLE) is a chronic neurological disease characterized by recurrent seizures. The pathogenic mechanisms underlying TLE involve defects in post-transcriptional regulation of gene expression. Previously we have shown the differences in cell compartment specific differential expression of coding transcripts in mTLE hippocampal and cortical samples compared to post-mortem controls (Vangoor et al., MedRxiv. 2021). On the same set of patient samples containing subcellular RNA from resected hippocampal (HC) and neo-cortical (Cx) tissue from mTLE no hippocampal sclerosis (non-HS) and mTLE HS International League Against Epilepsy (ILAE) Type 1 or mTLE+HS patients and postmortem control tissue, we applied small RNA sequencing (smRNA-seq). SmRNA-seq was analyzed for investigating the expression profiles of small non-coding RNA species as microRNAs and transferRNA fragments in human mTLE and control hippocampal tissue.
2024-11-06 | GSE245228 | GEO
Project description:The epilepsies represent one of the most common neurological disorders. Mesial temporal lobe epilepsies (MTLE) are the most frequent form of partial epilepsies and display frequent resistance to anti-epileptic drugs thus representing a major health care problem. In TLE, the origin of seizure activity typically involves the hippocampal formation, which displays major neuropathological features, described with the term hippocampal sclerosis (HS). HS is the most frequent pathological substrate of refractory mesial temporal lobe epilepsy. Complex partial seizures (CPS) are the predominant seizure type associated with medial temporal lobe epilepsy. MTLE is commonly due to mesial temporal sclerosis (MTS). The biology underlying the epilepstic seizures and the transcriptome associated to the seizure in intractable medial temporal lobe epilepsy is ill understood. The aim of the study was to identify potential biomarkers that could identify epileptic seizure. Thus we performed transcriptome profiling of ten medial temporal lobe epilepsy cases which are resistant to the drug and underwent temporal lobectomy. The cases constitutes of patients with intractable complex partial seizure, treated medically and have undergone detailed presurgical evaluation and subjected to surgery for standard temporal lobectomy and amygdalo-hippocampectomy. The spiking areas identified after the electrocorticography will form the test tissues, which compared with the nonspiking areas removed during the surgery, from the same patient. This could probably form one of the appropriate controls, as test and control are from same patient, which eliminates the genome variations that could incur due to the comparison with the tissues from the another patient. Also this could get rid of expression changes due to the treatments undergone by the patient. We performed two color microarray wherein we labled seizure focus (spiking area) with Cy5 and non-seizure region tissues (non-spiking) with Cy3. As a strategy to test the possibility of potential diagnostic biomarkers we are intended to test the differentially regulated molecules in an independent set of epilepsy samples.
2012-12-01 | GSE25453 | GEO